Vítejte!
Statistical Software in Bioequivalence

Helmut Schütz
BEBAC
Software only?

- Pentium FDIV bug (1993)
  - Flaw in the x86 assembly language floating point division
  - Example
    
    \[
    \frac{4,195,835}{3,145,727} = 1.333739068902037589
    \]
    
    \[
    \frac{4,195,835}{3,145,727} = 1.333820449136241002
    \]
  - Costs for replacement: $475 million

- Radiation therapy machine (Atomic Energy of Canada Ltd)
  - Direct electron-beam therapy: Low doses of high-energy (5 – 25 MeV) electrons over short periods of time.
  - Megavolt X-ray therapy: X-rays produced by colliding high-energy (25 MeV) electrons into a target.
- A one-byte counter in a testing routine frequently overflowed. If an operator provided manual input to the machine at the precise moment that this counter overflowed, the machine switched between operating modes. Patients received ~100 – 1,000 times the intended dose.
- Several patients injured, three died.
Mostly Software

- General Principles of Software Validation (FDA 2002)
  - Section 2.4: Regulatory Requirements for Software Validation
    - 242 FDA Medical Device Recalls attributed to software failures (1992 – 1998)
    - 192 (79%) caused by software defects that were introduced when changes were made to the software after its initial production and distribution.
Mostly Software

● General Principles of Software Validation (FDA 2002)

Section 2.4 (cont’d)

■ Any software [...] must be validated for its intended use.

■ Computer systems must be validated to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records.

■ All [...] software, even if purchased off-the-shelf, should have documented requirements that fully define its intended use, and information against which testing results and other evidence can be compared, to show that the software is validated for its intended use.
**Lines of Code (LOC)**

- **80/20-Rule**
  - 80% of lines coded within 20% of time
  - Changing and testing is the most tedious part
    - Average coding + testing: 10 – 50 LOC / day
    - 1 defect / 2,000 lines considered “stable”

<table>
<thead>
<tr>
<th>software</th>
<th>year</th>
<th>10⁶ LOC</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS-DOS</td>
<td>1981</td>
<td>0.004</td>
</tr>
<tr>
<td>Win 3.1</td>
<td>1992</td>
<td>3</td>
</tr>
<tr>
<td>Win NT 4.0</td>
<td>1996</td>
<td>12</td>
</tr>
<tr>
<td>Win XP</td>
<td>2001</td>
<td>45</td>
</tr>
<tr>
<td>Win 8</td>
<td>2012</td>
<td>60</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>software</th>
<th>year</th>
<th>10⁶ LOC</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS Office</td>
<td>2013</td>
<td>45</td>
</tr>
<tr>
<td>Photoshop 1</td>
<td>1990</td>
<td>0.1</td>
</tr>
<tr>
<td>PS CS 6</td>
<td>2012</td>
<td>5</td>
</tr>
<tr>
<td>Mac OS X</td>
<td>2005</td>
<td>85</td>
</tr>
<tr>
<td>Linux 3.6</td>
<td>2012</td>
<td>16</td>
</tr>
</tbody>
</table>
Some Terms

- **IEEE (610, 1028), ISO, and ISTQB**
  - **Error:** A human action that produces an incorrect result.
  - **Defect:** A flaw in a component or system that can cause the component or system to fail to perform its required function, e.g. an incorrect statement or data definition.
  - **Failure:** Deviation of the component or system from its expected delivery, service or result.
  - **Example:** Division by zero
    - **Error:** 0 as a user entry was not tested/trapped.
    - **Defect:** The program is (unnoticed) erroneous till data entry.
    - **Failure:** Runtime error during execution.
More Terms

**ISO 9000 and FDA (1999)**

- **Qualification**: The process of demonstrating the ability to fulfill specified requirements (the term ‘qualified’ is used to designate the corresponding status).
  - **Installation Q**: [...] systems are compliant with appropriate codes and approved design intentions, and that vendor’s recommendations are suitably considered.
  - **Operational Q**: [...] systems are capable of consistently operating within stated limits and tolerances.
  - **Performance Q**: [...] meeting all release requirements for functionality and safety and that procedures are effective and reproducible.
Qualification(s)...

- **Examples**
  - Each of the Qualification(s) should include an instruction, an expected result, and the actual result. Any discrepancy between the expected result and the actual result should be tracked as a deviation. Deviations should be resolved before validation is complete.

- **Installation Qualification**
  - The OS has the appropriate processor, RAM, etc.
  - All files required to run the system are present and access rights are granted.
  - All documentation required to train system personnel has been approved.
Qualification(s)...

Examples

- Operational Qualification
  - System security has been properly implemented.
  - All documentation required to train personnel has been approved.
  - Data entry / import accepts appropriate data and rejects inappropriate ones.
  - Data export is compliant with specifications.
  - Test datasets can be moved through an entire workflow.
  - (Technological controls for compliance with 21 CFR 11 are functioning as expected.)
  - ...

Qualification(s)...

Examples

- Performance Qualification
  - Test datasets’ results are within defined system requirements.
  - Concurrent independent workflows do not affect each other.
  - The system can handle multiple users without significant system lag.
  - ...

Confusion?

• General Principles of Software Validation (FDA 2002)
  • Section 3.1.3: IQ/OQ/PQ
    • [...] FDA and regulated industry have attempted to understand and define software validation within the context of process validation terminology.
    • While IQ/OQ/PQ terminology has served its purpose well and is one of many legitimate ways to organize software validation tasks at the user site, this terminology may not be well understood among many software professionals [...]. However, both FDA personnel and [...] manufacturers need to be aware of these differences in terminology as they ask for and provide information regarding software validation.
**System Life Cycle (V Model)**

- **Initialisation**
- **High Level Risk Assessment**
- **User Requirement Specifications**
- **System Design Specifications**
- **Module Design Specifications**
- **Module Development**
- **Module Test**
- **Installation Qualification**
- **Operational Qualification**
- **Performance Qualification**
- **System in Operation (validated)**
- **System Retirement**
- **Change Control**

**Dependency Arrows**
- Tested against
- User Requirement Specifications
- System Design Specifications
- Module Design Specifications
- Module Development
- Module Test
- Installation Qualification
- Operational Qualification
- Performance Qualification
- System in Operation (validated)
- System Retirement

**High Level Risk Assessment** is tested against all specifications.

**Change Control** controls the overall process.

**User** interacts with the system through the **Vendor**.

**References**:
- Esch et al.; *Good Laboratory Practice (GLP) – Guidelines for the Validation of Computerised Systems* (2007)
Responsibilities

- Part of the SLC can be performed in close collaboration with the vendor
  - Defining Functional Specifications and the Risk Assessment.
  - Performing Installation and Operational Qualification.
  - Running a large installation without a current support contract is grossly negligent.

- However, other parts are the sole responsibility of the user (e.g. Performance Qualification)
Responsibilities

- The ultimate responsibility in a controlled environment lies in the user’s hands
  - Full control of the SLC *only* possible for in-house developed software and *mostly* for outsourced developed one.
  - Try to get access to the source code for independent review (“white box” validation).
  - If not possible (vendor refuses an audit), perform a “black box” validation.
Responsibilities

The ultimate responsibility (cont’d)

“Black box” validation

- Run datasets with certified results (e.g. from NIST’s Statistical Reference Datasets Project).
  - FDA (2002): Testing with usual inputs is necessary. However, testing a software product only with expected, valid inputs does not thoroughly test that software product. By itself, normal case testing cannot provide sufficient confidence in the dependability of the software product.
- Create “worst-case” datasets (extreme range of input, non-numeric, enter floating point numbers to integer fields, …)
Responsibilities

● The ultimate responsibility (cont’d)
  ■ “Black box” validation
    ■ “Worst-case” datasets …
      ● FDA (2002): Software testing should demonstrate that a software product behaves correctly when given unexpected, invalid inputs. Methods for identifying a sufficient set of such test cases include Equivalence Class Partitioning, Boundary Value Analysis, and Special Case Identification (Error Guessing). While important and necessary, these techniques do not ensure that all of the most appropriate challenges to a software product have been identified for testing.
    ■ Cross-validate against another software.
Responsibilities

The ultimate responsibility (cont’d)

- Section 5.2.7 Maintenance & Software Changes (FDA 2002)
  - Corrective: Changes made to correct errors and faults.
  - Perfective: Changes made to improve the performance, maintainability, or other attributes.
  - Adaptive: Changes to make the software usable in a changed environment.
  - Sufficient […] analysis and testing should […] demonstrate that portions of the software not involved in the change were not adversely impacted (in addition to testing […] the correctness of the implemented changes).
## Computer System Validation (CSV)

### Analogies to a GLP study

<table>
<thead>
<tr>
<th>GLP study</th>
<th>CSV</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study director</td>
<td>Validation director</td>
<td>Ultimate responsibility</td>
</tr>
<tr>
<td>Study plan</td>
<td>Validation plan</td>
<td>Approved/signed by SD/VD</td>
</tr>
<tr>
<td>Method description</td>
<td>Test scripts</td>
<td>Referenced to or included in plan</td>
</tr>
<tr>
<td>Condtuct</td>
<td></td>
<td>Executing according to plan &amp; methods/scripts</td>
</tr>
<tr>
<td>Raw data</td>
<td></td>
<td>Documented evidence of test results</td>
</tr>
<tr>
<td>Study report</td>
<td>Validation report</td>
<td>Audited by QA and approved/signed by SD/VD</td>
</tr>
</tbody>
</table>
Spreadsheets?

- **Radio Yerevan Jokes**
  - Radio Yerevan was asked: "Is it possible to validate M$ Excel?"
  - Radio Yerevan anwered: "In principle yes, but only if you buy the source code from Mr Gates first."

- **EMA CPMP/CHMP/EWP (Q&A 2011–2015)**
  - Results obtained by alternative, validated statistical programs are also acceptable except spreadsheets because outputs of spreadsheets are not suitable for secondary assessment.

Esch et al.; Good Laboratory Practice (GLP) – Guidelines for the Development and Validation of Spreadsheets (2010)
Spreadsheets?

- **M$ Excel 1985 – 2002**

<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0 formula (A)</td>
<td>100,000,000</td>
<td>formula (C)</td>
<td>1</td>
<td>formula (E)</td>
</tr>
<tr>
<td>2</td>
<td>-1 =A$1–1</td>
<td>99,999,999</td>
<td>=C$1–1</td>
<td>0.999999999</td>
<td>=E$1–0.00000001</td>
</tr>
<tr>
<td>3</td>
<td>±0 =A$1</td>
<td>100,000,000</td>
<td>=C$1</td>
<td>1.000000000</td>
<td>=E$1</td>
</tr>
<tr>
<td>4</td>
<td>+1 =A$1+1</td>
<td>100,000,001</td>
<td>=C$1+1</td>
<td>1.000000001</td>
<td>=E$1+0.00000001</td>
</tr>
<tr>
<td>5</td>
<td>1 =STDEV(A2:A4)</td>
<td>0 =STDEV(C2:C4)</td>
<td>0 =STDEV(E2:E4)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- In calculating the 90% CI we use a table of the \( t \)-distribution (for \( \alpha \) 0.05 and df). For df 22 we get 1.717. However, in Excel ≤2007:

<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
<th>F</th>
<th>G</th>
<th>H</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>α</td>
<td>df</td>
<td>t</td>
<td>formula (C)</td>
<td>t</td>
<td>workaround (E)</td>
<td>t</td>
</tr>
<tr>
<td>2</td>
<td>0.05</td>
<td>22</td>
<td>2.074</td>
<td>=TINV(A2, B2)</td>
<td>1.717</td>
<td>=TINV(2*A2, B2)</td>
<td>1.717</td>
</tr>
</tbody>
</table>

M$ Article 828888: “You can expect that for most users, such round off errors are not likely to be troubling in practice.”
Open Source Software?

“**In principle yes – if it’s validated, why not?**”

- Since the source code is accessible, even a “white box” validation (which no off-the-shelf software offers) is possible.
  - The FDA regularly uses R in M & S itself (but – as an agency – never validates anything…).
  - New releases/updates more frequent than commercial SW
    - R & packages: 3 – 4 / year
    - Bugs in packages: Generally corrected within one week

Alterations of Data possible?

*Example: Phoenix/WinNonlin*

If software allows changes without an audit trail, take measures!

PKS is 21 CFR 11 compliant...
Document as far as possible

- Example: Phoenix/WinNonlin

Always select the Core Output (off by default)
Document as far as possible

Example: Phoenix/WinNonlin

Only in the Core Output you get a timestamp of the evaluation. Forget fancy Excel- or Word-Export options (if possible).
Old Hats...

Parallel Groups: Example

- Evaluation (modified data set)

<table>
<thead>
<tr>
<th>Program</th>
<th>equal variances</th>
<th>unequal variances</th>
</tr>
</thead>
<tbody>
<tr>
<td>R 2.5.0 (2007)</td>
<td>81.21% – 190.41%</td>
<td>76.36% – 202.51%</td>
</tr>
<tr>
<td>NCSS 2001 (2001)</td>
<td>81.21% – 190.41%</td>
<td>76.36% – 202.51%</td>
</tr>
</tbody>
</table>

- Inflated $\alpha$-risk in ‘conventional’ $t$-test (naive pooling) is reflected in a tighter confidence interval.
- Preliminary testing for equality in variances is flawed*) and should be avoided (FDA).
- Approximations (e.g., Satterthwaite, Aspin-Welch, Howe, Milliken-Johnson) are currently not implemented in packages ‘specialized’ in BE (WinNonlin, Kinetta, EquivTest/PK!)


Surprise?
Reference Datasets in BE

- Different software (general purpose, specialized in BE, commercial and open source), 2×2×2 crossover

<table>
<thead>
<tr>
<th>DS</th>
<th>EquivTest</th>
<th>Kinetica</th>
<th>SAS</th>
<th>WinNonlin</th>
<th>R</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>90.76</td>
<td>99.62</td>
<td>90.76</td>
<td>99.62</td>
<td>90.76</td>
</tr>
<tr>
<td>B</td>
<td>51.45</td>
<td>98.26</td>
<td>51.45</td>
<td>98.26</td>
<td>51.45</td>
</tr>
<tr>
<td>C</td>
<td>39.41</td>
<td>87.03</td>
<td><strong>44.91</strong></td>
<td><strong>99.31</strong></td>
<td>39.41</td>
</tr>
<tr>
<td>D</td>
<td>51.45</td>
<td>98.26</td>
<td>51.45</td>
<td>98.26</td>
<td>51.45</td>
</tr>
<tr>
<td>E</td>
<td>55.71</td>
<td>151.37</td>
<td>55.71</td>
<td>151.37</td>
<td>55.71</td>
</tr>
<tr>
<td>F</td>
<td>93.37</td>
<td>106.86</td>
<td>93.37</td>
<td>106.86</td>
<td>93.37</td>
</tr>
<tr>
<td>G</td>
<td>88.46</td>
<td>95.99</td>
<td>88.46</td>
<td>95.99</td>
<td>88.46</td>
</tr>
<tr>
<td>H</td>
<td>86.81</td>
<td>100.55</td>
<td><strong>107.80</strong></td>
<td><strong>115.85</strong></td>
<td>86.81</td>
</tr>
</tbody>
</table>

A, B, D – G: Balanced \( n_{TR} = n_{RT} \)
C, H: Imbalanced \( n_{TR} \neq n_{RT} \)

Schütz H, Labes D, Fuglsang A; *Reference Datasets for 2-Treatment, 2-Sequence, 2-Period Bioequivalence Studies* (2014)
### Reference Datasets in BE

#### Two-group parallel (conventional $t$-test)

<table>
<thead>
<tr>
<th>DS</th>
<th>EquivTest</th>
<th>Kinetica</th>
<th>SAS</th>
<th>WinNonlin</th>
<th>OO Calc</th>
<th>R</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>27.15</td>
<td>86.94</td>
<td>27.15</td>
<td>86.94</td>
<td>27.15</td>
<td>86.94</td>
</tr>
<tr>
<td>2</td>
<td>18.26</td>
<td>96.59</td>
<td>15.76</td>
<td>119.00</td>
<td>18.26</td>
<td>96.59</td>
</tr>
<tr>
<td>3</td>
<td>26.35</td>
<td>415.71</td>
<td>26.35</td>
<td>415.71</td>
<td>26.35</td>
<td>415.71</td>
</tr>
<tr>
<td>4</td>
<td>38.60</td>
<td>134.21</td>
<td>38.60</td>
<td>134.21</td>
<td>38.60</td>
<td>134.21</td>
</tr>
<tr>
<td>5</td>
<td>106.44</td>
<td>112.10</td>
<td>106.39</td>
<td>112.44</td>
<td>106.44</td>
<td>112.10</td>
</tr>
<tr>
<td>6</td>
<td>91.85</td>
<td>115.78</td>
<td>92.07</td>
<td>115.50</td>
<td>91.85</td>
<td>115.78</td>
</tr>
<tr>
<td>7</td>
<td>106.86</td>
<td>126.49</td>
<td>104.30</td>
<td>129.32</td>
<td>106.86</td>
<td>126.49</td>
</tr>
<tr>
<td>8</td>
<td>105.79</td>
<td>113.49</td>
<td>105.79</td>
<td>113.49</td>
<td>105.79</td>
<td>113.49</td>
</tr>
<tr>
<td>9</td>
<td>103.80</td>
<td>120.61</td>
<td>103.80</td>
<td>120.61</td>
<td>103.80</td>
<td>120.61</td>
</tr>
<tr>
<td>10</td>
<td>107.20</td>
<td>126.99</td>
<td>104.59</td>
<td>130.16</td>
<td>107.20</td>
<td>126.99</td>
</tr>
<tr>
<td>11</td>
<td>7.83</td>
<td>17.38</td>
<td>6.98</td>
<td>19.51</td>
<td>7.83</td>
<td>17.38</td>
</tr>
</tbody>
</table>

1, 3, 4, 8, 9  Equal group sizes ($n_T = n_R$)
2, 5 – 7, 10, 11 Unequal group sizes ($n_T \neq n_R$)
### Reference Datasets in BE

#### Two-group parallel (Welch’s test)

<table>
<thead>
<tr>
<th>DS</th>
<th>SAS</th>
<th>WinNonlin*</th>
<th>OO Calc</th>
<th>R</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>26.78</td>
<td>88.14</td>
<td>26.78</td>
<td>88.14</td>
</tr>
<tr>
<td>2</td>
<td>23.71</td>
<td>74.38</td>
<td>23.71</td>
<td>74.38</td>
</tr>
<tr>
<td>3</td>
<td>24.40</td>
<td>449.08</td>
<td>24.40</td>
<td>449.08</td>
</tr>
<tr>
<td>4</td>
<td>38.05</td>
<td>136.15</td>
<td>38.05</td>
<td>136.15</td>
</tr>
<tr>
<td>5</td>
<td>106.44</td>
<td>112.10</td>
<td>106.44</td>
<td>112.10</td>
</tr>
<tr>
<td>6</td>
<td>91.84</td>
<td>115.79</td>
<td>91.84</td>
<td>115.79</td>
</tr>
<tr>
<td>7</td>
<td>97.38</td>
<td>138.51</td>
<td>NA</td>
<td>97.38</td>
</tr>
<tr>
<td>8</td>
<td>105.79</td>
<td>113.49</td>
<td>NA</td>
<td>105.79</td>
</tr>
<tr>
<td>9</td>
<td>103.80</td>
<td>120.61</td>
<td>NA</td>
<td>103.80</td>
</tr>
<tr>
<td>10</td>
<td>97.82</td>
<td>139.17</td>
<td>NA</td>
<td>97.82</td>
</tr>
<tr>
<td>11</td>
<td>6.30</td>
<td>21.60</td>
<td>NA</td>
<td>6.30</td>
</tr>
</tbody>
</table>

* Workaround required in WinNonlin; limited to 1,000 subjects.

Welch’s test not implemented in EquivTest and Kinetica.

---

Likely Cause of Kinetica’s Defects

● 2×2×2 crossover

\[
\ln(\bar{x}_T - \bar{x}_R) \pm t_{\alpha, \nu} \sqrt{\frac{MSE}{2}} \left( \frac{1}{n_{TR}} + \frac{1}{n_{RT}} \right)
\]

\[CI = e\]

Only if sequences are balanced \((n_{TR} = n_{TR})\) a simplified formula based on the total sample size \(N\) is correct:

\[
\ln(\bar{x}_T - \bar{x}_R) \pm t_{\alpha, \nu} \sqrt{\frac{2MSE}{N}}
\]

\[CI = e\]
Likely Cause of Kinetica’s Defects

- Two-group parallel

\[
\ln(\bar{x}_T - \bar{x}_R) \pm t_{\alpha,\nu} \sqrt{\frac{MSE}{\frac{1}{n_T} + \frac{1}{n_R}}} \]

\[CI = e\]

According to the manual Kinetica uses a “simplified” formula – but the sample size of subjects receiving the reference \([sic]\) treatment in the denominator:

\[
\ln(\bar{x}_T - \bar{x}_R) \pm t_{\alpha,\nu} \sqrt{2MSE \over n_R} \]

\[CI = e\]
Thank You!
Statistical Software in Bioequivalence
Open Questions?

Helmut Schütz
BEBAC
Consultancy Services for
Bioequivalence and Bioavailability Studies
1070 Vienna, Austria
helmut.schuetz@bebac.at
To bear in Remembrance...

A refund for defective software might be nice, except it would bankrupt the entire software industry in the first year.

*Andrew S. Tannenbaum*

If debugging is the process of removing bugs, then programming must be the process of putting them in.

*Edsger W. Dijkstra*

I have stopped reading Stephen King novels. Now I just read C code instead.

*Richard O’Keefe*
References

- **EMA**
  - Q & A (2011): *Positions on specific questions addressed to the EWP therapeutic subgroup on Pharmacokinetics* [URL]
  - Annex III to Procedure for Conducting GCP Inspections requested by the EMEA: Computer Systems (2007) [URL]
- **US FDA**
  - CDRH-ODE (1999): *Gf, FDA Reviewers and Compliance on Off-The-Shelf Software Use in Medical Devices* [URL]
  - CDRH, CBER (2002): *General Principles of Software Validation* [URL]
  - OC (2007): *Computerized Systems Used in Clinical Investigations* [URL]
- **PIC/S** – Good Practices for Computerised Systems in Regulated “GxP” Environments (2007) [URL]
- **Switzerland, Federal Office of Public Health, AGIT**
  - Validation of computerised systems in GLP (2007) [URL]
  - Management of electronic SOPs in GLP (2006) [URL]
  - Acquisition and processing of electronic raw data in a GLP environment (2006) [URL]
  - Change Management and Risk Assessment of validated computerised systems in a GLP environment (2012) [URL]
- **International Software Testing Qualifications Board**
  - Standard Glossary of Terms used in Software Testing (2014) [URL]
- **OECD**
- **International Society for Pharmaceutical Engineering: GAMP®**
  - *A Risk-Based Approach to Compliant GxP Computerized Systems* (2008)
  - *Good Practice Guide: A Risk-Based Approach to GxP Compliant Laboratory Computerized Systems* (2nd ed 2012)
- **Chamberlain R (1991)**
  - Computer Systems Validation for the Pharmaceutical and Medical Device Industry
- **Stokes et al. (1994)**
  - Good Computer Validation Practices
  - Interpharm, Buffalo Grove, IL. ISBN 0-935184-55-4
- **Olivier D (1994)**
  - Conducting Software Audits, Auditing Software for Conformance to FDA Requirements
  - Computer Application Specialists, San Diego, CA.
References

- Beizer B (1995)
  *Black Box Testing. Techniques for Functional Testing of Software and Systems*
- Fry JD, Drew RT (1992)
  *Creation and Implementation of a Computer Validation Program*
  *Medical Devices: The Therac-25* URL
  *Good laboratory practice (GLP). Guidelines for the archiving of electronic raw data in a GLP environment*
  Qual Assur J 7(4), 262–9 doi:10.1002/qaj.244
  *Good Laboratory Practice (GLP) – Guidelines for the Acquisition and Processing of Electronic Raw Data in a GLP Environment*
  *Good Laboratory Practice (GLP) – Guidelines for the Validation of Computerised Systems*
  *Good Laboratory Practice (GLP) – Guidelines for the Development and Validation of Spreadsheets*
  Qual Assur J 13(3–4), 41–56 doi:10.1002/qaj.466
- Microsoft Knowledge Base – Article ID: 82634
  *Description of the STDEV function in Excel 2003 and in later versions of Excel*
  Last Review: September 19, 2011; Revision: 4.0
  *R: Regulatory Compliance and Validation Issues. A Guidance Document for the Use of R in Regulated Clinical Trial Environments* URL
  *Reference Datasets for 2-Treatment, 2-Sequence, 2-Period Bioequivalence Studies*
  AAPS J 16(6), 1292–7 doi:10.1208/s12248-014-9661-0
  *Reference Datasets for Bioequivalence Trials in a Two-Group Parallel Design*
  AAPS J 17(2), 400–4 doi:10.1208/s12248-014-9704-6
- Moralez-Acelay S, de la Torr de Alvarado JM, García-Arieta A
  *On the Incorrect Statistical Calculations of the Kinetica Software Package in Imbalanced Designs*
  AAPS J (Epub 19 March 2015) doi:10.1208/s12248-015-9749-1